Sponsored by
Latest
Topics
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Featured
Financial Planning and Analysis
92% of CFOs Say They’re Fully Prepared for a Recession: Weekly Stat
CFO self-assurance around their performance, the economy, and their ability to ride out a recession are high, per recent CFO research.
By
Adam Zaki
| February 8, 2023
Read More
Resources
CFO Live
2022 Survey
Sign Up
Menu
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Explore
Search
Latest
Resources
CFO Live
2022 Survey
Sign Up
Sponsored by
cancer drugs
M&A
Gilead to Buy Forty Seven for $4.9B
The deal adds to Gilead's presence in immuno-oncology, an approach to treating cancer that harnesses the body's immune system.
By
Lauren Muskett
| March 2, 2020
Read More
M&A
Merck, Sanofi in Deals for Cancer Drug Firms
The pharma giants each announced they would buy smaller drugmakers to expand cancer-treatment franchises.
By
Lauren Muskett
| December 9, 2019
Read More
M&A
Bristol-Myers to Buy Big Pharma Rival Celgene
The $74 billion deal could create the fourth-largest U.S. pharma firm, with a portfolio that includes nine blockbuster drugs.
By
Matthew Heller
| January 3, 2019
Read More
Strategy
Glaxo Makes $5.1B Move Into Cancer Drugs
The acquisition of Tesaro fits Glaxo's focus on gene-based therapies but investors are concerned it is paying too steep a price.
By
Matthew Heller
| December 3, 2018
Read More
Financial Performance
J&J Gets Boost From Strong Cancer Drug Sales
The company's Q3 earnings beat estimates but "it remains too early to call for a broad recovery" in the medical-device and consumer businesses.
By
Matthew Heller
| October 16, 2018
Read More
Strategy
Roche Takes Full Control of Genomic Profiler
The $2.4 billion purchase of 44% of Foundation Medicine raises Roche's bet on the development of personalized cancer treatments and care.
By
Matthew Heller
| June 19, 2018
Read More
Strategy
Takeda Buys Ariad in $5.2B Cancer Drug Bet
The Japanese drug giant is paying a 75% premium for Ariad to "transform our global solid tumor franchise."
By
Matthew Heller
| January 10, 2017
Read More